Swetha Kambhampati retweeted
Developing the treatments of tomorrow is hard work. @DoctorAKrishnan, M.D., and @elizabeth_budde, M.D., Ph.D., are leading a few clinical trials related to bispecific antibodies and their ability to target cancer cells more precisely than chemo. https://teapawt.net/t.co/to7k4B0llm #HemOnc
Swetha Kambhampati retweeted
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in patients with relapsed or refractory LBCL, according to the primary OS analysis of the phase III ZUMA-7 study released by @KitePharma.
bloodcancerstoday.com/post/z…
Swetha Kambhampati retweeted
🔊OUT NOW: This all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, about the cost effectiveness of pola-R-CHP in relation to other therapies for DLBCL.
@SocietyofHemOnc
bloodcancerstoday.com/podcas…
Swetha Kambhampati retweeted
Huge news! ZUMA-7 trial shows axi-cel improves overall survival in patients with second-line aggressive lymphoma, compared to chemo/autoSCT. Statistically significant, which should end the “try chemo first” argument. Full data to be presented in the next few months. #lymsm
#NEWS: Today, we announced the primary overall survival (OS) analysis results, a key secondary endpoint, of our Phase 3 study of CAR T-cell therapy for initial treatment of relapsed/refractory large B-cell lymphoma.
Swetha Kambhampati retweeted
Dr. Ayushi Chauhan @Chauhan_AF from @GACancerCenter named the 2023 Stephanie A. Gregory Distinguished Scholar by the Lymphoma Research Foundation @lymphoma. A brilliant young investigator. Very proud of her accomplishments.
Swetha Kambhampati retweeted
🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies.
@SocietyofHemOnc
Swetha Kambhampati retweeted
Excited the City of Hope experience with bridging therapy prior to CAR T for LBCL is published. Thanks for the collaboration between @COH_RadOnc and @COHMedOnc. Stay tuned for our prospective trial shortly! mdpi.com/2072-6694/15/6/1747
Swetha Kambhampati retweeted
Great group at the LRF Sci Res Mentoring Program in Las Vegas @DrCarlaCasulo @SwethaKMD
Swetha Kambhampati retweeted
#Tandem23 | @SwethaKMD of @cityofhope discusses real-world outcomes of patients with transformed R/R DLBCL treated with CAR-T therapy:
👉ow.ly/Hsb550N5GV4👈
@ASTCT @CIBMTR #DLBCL #LymSM #CARTcell #ImmunoOnc
Swetha Kambhampati retweeted
Pola-R-CHP can be more cost-effective than R-CHOP in patients with treatment-naïve DLBCL in certain circumstances, according to an analysis by @SwethaKMD, of @cityofhope.
bloodcancerstoday.com/post/p…
Swetha Kambhampati retweeted
Excited to share published multicenter project on comorbidities which are critical in CAR T-cell outcomes. With gratitude to @AdamKittai @LNastoupilMD @drjgauthier @DebbieMStephens @KrishPatelMD @mshadman @mana1981 and all collaborators! ashpublications.org/bloodadv…
Swetha Kambhampati retweeted
Congrats Carla!
💜 Congratulations @WomenInLymphoma 2023 Steering Committee Chair @DrCarlaCasulo
urmc.rochester.edu/people/28…
👏And many thanks 2022 Chair @DrLaCasce for a year packed with growth, accomplishments, advocacy, education & successes #womeninlymphoma #lymphoma @lymphomaOz @URMC_DeptMed
Swetha Kambhampati retweeted
Alex (not on Twitter! ) is one of the most passionate and dedicated physician and researcher you will ever meet. I got to know him as classmate and later as co-faculty at ASH CRTI workshop. A true friend and colleague. 🙏🏽🙏🏽👏👏
cc @doctorpemm
Important profile piece featuring Dr Alex Herrera #lymsm || ascopost.com/issues/december… | @ASCO @ASCOPost
Swetha Kambhampati retweeted
Our phase 1 trial on Pevonedistat+Ibrutinib in B cell lymphomas is out in #BloodCancerJournal
nature.com/articles/s41408-0…
PEVO is a Nedd8 activating enzyme inhibitor with preclinical activity in CLL (@danilovlab), MCL (#HernandezLab @roswellpark) and DLBCL (Torka et al, #EJHaem).
Swetha Kambhampati retweeted
KSHV viral load in CSF predicts involvement by primary effusion #lymphoma
KSHV VL >391 copies/mL:
Sensitivity=100% Specificity=94% to detect PEL
+LR=17 -LR=0
Potential screening tool in low-resource settings with limited pathology services #HIVonc
haematologica.org/article/vi…
Swetha Kambhampati retweeted
gene.com/media/press-release… Mosunetuzumab was approved by the FDA hours ago for 3L+ FL! No REMS requirement. So emotional now. Thankful to all the patients enrolled on the trial. Congrats to all my co-investigators, research staff @cityofhope , global sites, @genentech
Swetha Kambhampati retweeted
Mosunetuzumab is approved by the @FDA for r/r #FL. Great news for pts who now have easier access to a potentially life saving dtug.
Also, the first CD20/CD3 bsab approved in the US.
onclive.com/view/fda-approve…
Swetha Kambhampati retweeted
Proud of @Eddie_Cliff for such an insightful commentary on @SwethaKMD cost effectiveness analysis of Pola-R-CHP vs R-CHOP published in @BloodJournal 👌🏼
ashpublications.org/blood/ar…
Swetha Kambhampati retweeted
Reword to add:
Please sponsor 'junior FEMALE colleagues' as they are routinely forgotten/overlooked for leadership roles.
70:30 ♂️:♀️ representation in editorial boards.
Kudos @HadidiSamer for this insightful study
@HemOncWomenDocs @WomeninOnc @WomenInLymphoma @womeninmedchat
This Post is from an account that no longer exists. Learn more
Swetha Kambhampati retweeted
So proud to be a part of this wonderful #oncology community! Hoping to serve you all well in this new role.
Dear Colleagues,
A warm round of applause to all of those who were chosen at the @ASCO elections 🗳️
Special Kudos to Dr. Robin Zon Elected ASCO President for 2024-2025 & our @OncoAlert 🚨 faculty/friend/colleague @montypal of @cityofhope who enters the nominating committee ‼️





























